Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A case of a glomus tumor presenting as an atypical hyperkeratotic papule of the hypothenar palm.

Sanchez IM, Ilkovitch D.

JAAD Case Rep. 2017 Dec 18;4(1):38-40. doi: 10.1016/j.jdcr.2017.10.006. eCollection 2018 Jan. No abstract available.

2.

Myeloid-derived suppressor cells are elevated in patients with psoriasis and produce various molecules.

Ilkovitch D, Ferris LK.

Mol Med Rep. 2016 Oct;14(4):3935-40. doi: 10.3892/mmr.2016.5685. Epub 2016 Aug 26.

3.

A Shot of Alcohol May be the Answer to Persistent Pyogenic Granulomas.

Ilkovitch D, Sam H.

Dermatol Surg. 2016 Sep;42(9):1119-20. doi: 10.1097/DSS.0000000000000781. No abstract available.

PMID:
27243135
4.

Brimonidine effective but may lead to significant rebound erythema.

Ilkovitch D, Pomerantz RG.

J Am Acad Dermatol. 2014 May;70(5):e109-10. doi: 10.1016/j.jaad.2014.01.853. No abstract available.

5.

Mechanisms of antitumor and immune-enhancing activities of MUC1/sec, a secreted form of mucin-1.

Ilkovitch D, Carrio R, Lopez DM.

Immunol Res. 2013 Dec;57(1-3):70-80. doi: 10.1007/s12026-013-8451-6. Review.

PMID:
24222275
6.

Is prurigo pigmentosa an inflammatory version of confluent and reticulated papillomatosis?

Ilkovitch D, Patton TJ.

J Am Acad Dermatol. 2013 Oct;69(4):e193-5. doi: 10.1016/j.jaad.2013.04.049. No abstract available.

PMID:
24034398
7.

uPA and uPA-receptor are involved in cancer-associated myeloid-derived suppressor cell accumulation.

Ilkovitch D, Carrio R, Lopez DM.

Anticancer Res. 2012 Oct;32(10):4263-70.

PMID:
23060546
8.

Role of immune-regulatory cells in skin pathology.

Ilkovitch D.

J Leukoc Biol. 2011 Jan;89(1):41-9. doi: 10.1189/jlb.0410229. Epub 2010 Jul 13. Review.

9.

Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells.

Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S.

J Immunol. 2009 Jul 15;183(2):937-44. doi: 10.4049/jimmunol.0804253. Epub 2009 Jun 24.

10.

The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression.

Ilkovitch D, Lopez DM.

Cancer Res. 2009 Jul 1;69(13):5514-21. doi: 10.1158/0008-5472.CAN-08-4625. Epub 2009 Jun 23.

11.

Decreased levels of both Stat1 and Stat3 in T lymphocytes from mice bearing mammary tumors.

Handel-Fernandez ME, Ilkovitch D, Iragavarapu-Charyulu V, Herbert LM, Lopez DM.

Anticancer Res. 2009 Jun;29(6):2051-8.

12.

Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated.

Torroella-Kouri M, Silvera R, Rodriguez D, Caso R, Shatry A, Opiela S, Ilkovitch D, Schwendener RA, Iragavarapu-Charyulu V, Cardentey Y, Strbo N, Lopez DM.

Cancer Res. 2009 Jun 1;69(11):4800-9. doi: 10.1158/0008-5472.CAN-08-3427. Epub 2009 May 19.

13.

Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec.

Ilkovitch D, Lopez DM.

Blood. 2009 May 7;113(19):4729-39. doi: 10.1182/blood-2008-08-176438. Epub 2009 Feb 4.

14.

Immune modulation by melanoma-derived factors.

Ilkovitch D, Lopez DM.

Exp Dermatol. 2008 Dec;17(12):977-85. doi: 10.1111/j.1600-0625.2008.00779.x. Epub 2008 Jul 17. Review.

PMID:
18643844
15.

Antitumor effects of Mucin 1/sec involves the modulation of urokinase-type plasminogen activator and signal transducer and activator of transcription 1 expression in tumor cells.

Ilkovitch D, Handel-Fernandez ME, Herbert LM, Lopez DM.

Cancer Res. 2008 Apr 1;68(7):2427-35. doi: 10.1158/0008-5472.CAN-07-5651.

16.

MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.

Ilkovitch D, Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2004 Jun;53(6):525-32. Epub 2004 Jan 17.

PMID:
14730400
17.

Invariant chain and the MHC class II cytoplasmic domains regulate localization of MHC class II molecules to lipid rafts in tumor cell-based vaccines.

Dolan BP, Phelan TP, Ilkovitch D, Qi L, Wade WF, Laufer TM, Ostrand-Rosenberg S.

J Immunol. 2004 Jan 15;172(2):907-14.

Supplemental Content

Loading ...
Support Center